In another departure from its core focus on genetic medicines, Vertex Pharma has agreed a $4.9 billion purchase of Alpine Immune Sciences, adding a mid-stage drug candidate for kidney disease IgA ...
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high growth high margin stocks to buy now. On January 28, Barclays began coverage of Vertex Pharmaceuticals Incorporated ...
Vertex Pharmaceuticals forecast 2026 revenue largely in line with analysts estimates on Thursday, as the drugmaker bets on growth for its cystic fibrosis treatments as well as contributions from newer ...
Vertex executives warned that Casgevy, its curative treatment for sickle cell disease, would be slow to reach patients. But ...
Max Verstappen will start the season-finale on pole position, as three world championship contenders bid for glory at the Abu Dhabi Grand Prix. The McLaren duo of Lando Norris and Oscar Piastri, plus ...
Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) jumped 6.2% in the afternoon session after Morgan Stanley upgraded its rating on the stock to "Overweight" from "Equal-Weight" and ...
Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...
Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...
During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...
Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results